Drug pricing

#Drug pricing #National Institute for Health and Care Excellence (NICE) #Rare disease

New NICE thresholds is good news for ultra-rare disease drugs, says biotech 

 The National Institute for Health and Care Excellence (NICE), the body that determines the clinical effectiveness and economic value of new medicines, has increased the cost-effectiveness thresholds it applies for drugs that qualify for their Highly Specialised Technology (HST) programme.  However, SynaptixBio, the only company licensed to… Read More

#Business & Investment #News

Drug prices concept
#Biopharmaceuticals #Drug pricing #Pharmaceutical industry #United States

What international reference pricing could mean for US drug costs

Andrew Mignatti, Co-Founder and CEO of careviso, looks at the possibility of the United States (US) adopting international reference pricing and asks if it is possible to lower drug costs without undermining innovation.  Discussion around international reference pricing (IRP) is intensifying as policymakers search for ways to… Read More

#Business & Investment #Exclusive Content #Opinion